Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models - Wikidata - thesis-toulmin - TriplyDB

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models

http://www.wikidata.org/entity/Q28473783

about

Identifying and targeting tumor-initiating cells in the treatment of breast cancer Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition Significance of PELP1 in ER-negative breast cancer metastasis Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.Two faces of TGF-beta1 in breast cancer.The four-transmembrane protein MAL2 and tumor protein D52 (TPD52) are highly expressed in colorectal cancer and correlated with poor prognosis Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.Isolation and characterization of a metastatic hybrid cell line generated by ER negative and ER positive breast cancer cells in mouse bone marrow.CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.Cationicity-enhanced analogues of the antimicrobial peptides, AcrAP1 and AcrAP2, from the venom of the scorpion, Androctonus crassicauda, display potent growth modulation effects on human cancer cell lines Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1 CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition.Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.Cancer stem cells and side population cells in breast cancer and metastasis.N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.A mechanism linking Id2-TGFβ crosstalk to reversible adaptive plasticity in neuroblastoma Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.Role of microRNAs in the regulation of breast cancer stem cells.Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.Therapeutic targets for bone metastases in breast cancer.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?Targeting the TGFβ signalling pathway in disease.FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.Blockade of Autocrine TGF-β Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells.Pathways to breast cancer recurrence.Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression.Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.

P2860

Q26851827-FE0674A1-38A0-45D4-8CC3-5072675F9ABA Q26858839-045AF77B-0AAD-403B-AD43-CA6E95467467 Q26864979-6E0D8678-AF5D-4F21-B9EC-F1F9658B3DE6 Q27303597-F6389043-CD34-471D-BACA-FC164ED5E69D Q27334832-00FF998B-A415-4541-9893-5D3CEE29A141 Q28253038-7A8C91CC-6E73-43D9-A36D-C80965EBD858 Q28297295-7684A856-1648-4104-8117-D00CD2D4C60E Q28393898-7CE4FC45-7CD3-46A6-8358-CFF34E5C0A9E Q30529813-62654954-743B-47A7-99A8-5538C238F80F Q33563230-C0814825-E176-4460-962D-4653953FBCA5 Q33661529-E7205C99-29C0-4BEB-B72F-431802C26086 Q33745941-520E40E2-3916-4E77-965E-A19E143AE32F Q33842777-4FC3B02B-75C4-4E7C-BFA6-986B49F409F8 Q33851448-E24F4101-F432-48CD-9761-9FCA751DB181 Q33932755-4264B0EF-B334-4B58-848F-F9ADAFDCFE4A Q34036076-EBB4C704-99C4-46E2-B8ED-C4F2998A6F2A Q34208986-5452580F-8A7C-4583-A914-0DDF27886FF7 Q34365171-385AFFF5-45D9-483C-A155-EDCA84CCCFE9 Q34486691-32CEA0B8-6952-4098-9645-37F0A3BCE328 Q34600387-0D99955B-E671-460D-AD4E-CA072EF599FF Q35029475-03DFCC11-ACD0-4E6A-8B3A-94F09EBF0187 Q35038054-9ADB370D-CE3D-4773-BC3A-CEE976E7F744 Q35051469-A13CB7CA-7210-4281-9123-CA0319FC9379 Q35078100-2AC115F1-67E2-4D44-AE84-09762200DB0A Q35117549-2A12E610-82FB-4692-BB82-38F2BF62D87A Q35190678-78A4759F-6A99-4912-B88A-60DCA8C041F7 Q35426250-A96EDD98-2084-40B5-AB3F-B0E63C18E083 Q35444029-3B03B4B1-CF8A-4EEE-BFAB-B1EECDFBA0EB Q35490960-F07EFA37-362A-4AF6-864B-39268BDDE3D7 Q35558919-595E1639-D5B9-4E1F-8C2B-6E8F8067A1F4 Q35604265-13A600C2-F27D-4F11-A080-1EF0E19B5B8A Q35741674-3BFA5D97-0AA6-4AD3-A785-28BD9D87DC5B Q35796826-3C6E7E73-0EB6-4673-975A-553A7127EF0C Q36429758-FBEB54EC-5F92-4B41-B838-29C29BAF84A3 Q36462348-6798F802-4D50-447D-8566-B489EAF1F8E9 Q36486689-BF846543-B66F-4F42-A92B-BCBAABFD7131 Q36670502-2C83493A-E26E-4740-BF3A-31894A0CB758 Q36702139-09CDA4AF-4DC4-41D5-B3DC-88E30F85E698 Q37044614-8E37219A-C2E0-4AF3-A4A8-0545434B7522 Q37412481-525E46BC-828D-43A9-A40D-1E5858D53EC8

P2860

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models

http://www.wikidata.org/entity/Q28473783

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Doxorubicin in combination wit ...... breast cancer in mouse models

@ast

Doxorubicin in combination wit ...... breast cancer in mouse models

@en

Doxorubicin in combination wit ...... breast cancer in mouse models

@nl

type

label

Doxorubicin in combination wit ...... breast cancer in mouse models

@ast

Doxorubicin in combination wit ...... breast cancer in mouse models

@en

Doxorubicin in combination wit ...... breast cancer in mouse models

@nl

prefLabel

Doxorubicin in combination wit ...... breast cancer in mouse models

@ast

Doxorubicin in combination wit ...... breast cancer in mouse models

@en

Doxorubicin in combination wit ...... breast cancer in mouse models

@nl

P1433

Q28473783-91E1760B-EE51-4F94-88A7-28309E995D33

P1476

Q28473783-7023B9D9-05E1-4F50-9EF7-83C94892C3C2

P2093

Q28473783-3228E730-8F7A-40BB-9F2C-72CFBBBBE469

Q28473783-3C6BBD21-D875-42F8-A418-9EFBDCB7BB30

Q28473783-3FAA83EC-8EAA-45AC-AACE-DEFC1D0F6D93

Q28473783-58A16D24-8C8F-4F85-A283-473B02C3960F

Q28473783-64D35D44-5236-4078-A65B-C8DB449F7494

Q28473783-821CEC98-FB7D-487B-8063-25164298FC7B

Q28473783-B8A9045E-0132-4CC6-9284-51AEAFBA6534

Q28473783-BE8E6FDB-1EEB-4F9F-80C7-46A84ED47EE9

P2860

Q28473783-014EEB00-BF8A-45A0-996F-0ED95C127A92

Q28473783-1286C5DC-6092-4548-B1E2-8B01147BCE0B

Q28473783-132F0868-865C-44CC-BD42-A591771561AE

Q28473783-1510C818-CBCE-477C-BD12-9413DDDD400B

Q28473783-15C8E4A3-19C3-43F8-AB79-217EC16C60B1

Q28473783-161D65FD-9D12-4A11-A93D-1D80525A467A

Q28473783-18902680-FF30-419C-B627-0E7A5199F3AF

Q28473783-211909FA-F4E9-43CD-B87B-FB59B7E83D64

Q28473783-30DFDFFE-C2F3-4CE4-B822-DFA853AE0F0D

Q28473783-34F9C889-5D88-42E3-A61C-70F69B568FCE

P304

Q28473783-C7A76287-8841-47D0-9A0D-748AE26A5A9D

P31

Q28473783-9C9720AE-F1B2-473D-A8BD-1642A2EE057B

P3181

Q28473783-D940F2D2-7961-4CD5-B67B-E0E6ECE89259

P356

Q28473783-FF96E46A-4FC0-4BC6-99F8-C6B0C4577CA6

P407

Q28473783-C65B1851-C204-4791-83A0-EFE43B6FD5EE

P433

Q28473783-B578E6BB-7DDF-43EB-9E6E-D6EC48657B5E

P478

Q28473783-8417134B-8079-482D-9CBC-F9C1ABD741A0

P577

Q28473783-CDF8E6A7-26FA-44CA-86C0-1EF2FA3D73DF

P5875

Q28473783-5B84507E-DB91-4D62-A9CD-CFAA1CF3D927

P698

Q28473783-1093CECC-0492-4CC1-A362-E7C75E24DD0E

P932

Q28473783-3C971BB9-E262-420F-9013-4BE74F034B3F

P3181

P356

JOURNAL.PONE.0010365

P1433

P1476

Doxorubicin in combination wit ...... breast cancer in mouse models

@en

P2093

Abhik Bandyopadhyay

http://www.w3.org/2001/XMLSchema#string

I-Tien Yeh

http://www.w3.org/2001/XMLSchema#string

Joseph Agyin

http://www.w3.org/2001/XMLSchema#string

Keya De

http://www.w3.org/2001/XMLSchema#string

Long Wang

http://www.w3.org/2001/XMLSchema#string

Lu-Zhe Sun

http://www.w3.org/2001/XMLSchema#string

Shu Lin

http://www.w3.org/2001/XMLSchema#string

Yuping Tang

http://www.w3.org/2001/XMLSchema#string

P2860

The epithelial-mesenchymal transition generates cells with properties of stem cells

Global cancer statistics, 2002

Molecular definition of breast tumor heterogeneity

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors

Generation of breast cancer stem cells through epithelial-mesenchymal transition

TGF-beta-induced epithelial to mesenchymal transition

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature

Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population.

Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.

P304

e10365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4131093

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0010365

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44573452

http://www.w3.org/2001/XMLSchema#string

P698

20442777

http://www.w3.org/2001/XMLSchema#string

P932

2860989

http://www.w3.org/2001/XMLSchema#string